Company / R&D Expense
PALVELLA THERAPEUTICS, INC. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$8.2M
FY2024
5-year range
$8.2M / $55.0M
FY2020-FY2024
Trend
-7.3%
vs FY2023
Sector context
#205 of 210
Health Care
What the data says
Among 210 Health Care companies, PALVELLA THERAPEUTICS, INC. is in the bottom 2% for r&d expense. Declined from $53M to $8M over the past 2 years.
Based on SEC 10-K filings.
$8M in FY2024 with a 5-year CAGR of -31.7%.
Declined from $53M to $8M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -44.0%
- 5-Year CAGR
- -31.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 210This company $8.2M Sector average $644.0M
▼
-98.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -31.7%, indicating a declining trend.
- In FY2024, r&d expense decreased 7.3% year-over-year.
- Ranks #205 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.2M | -7.3% |
| FY2023 | $8.8M | -83.4% |
| FY2022 | $53.0M | +13.9% |
| FY2021 | $46.5M | -15.4% |
| FY2020 | $55.0M | +0.0% |
| FY2019 | $55.0M | +146.8% |
| FY2018 | $22.3M | +13.1% |
| FY2017 | $19.7M | +0.0% |
| FY2016 | $19.7M | +138.9% |
| FY2015 | $8.2M | +47.2% |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026